PL2133091T3 - Kompozycje zawierające supramolekularne układy insuliny użyteczne do leczenia cukrzycy - Google Patents

Kompozycje zawierające supramolekularne układy insuliny użyteczne do leczenia cukrzycy

Info

Publication number: PL2133091T3
Authority: PL; Poland
Prior art keywords: diabetes; compositions; treatment; supramolecular insulin; assemblies useful
Prior art date: 2008-04-07

Application number

PL09155775T

Other languages

English (en)

Inventor

Avadhesha Suriola

Sarika Gupta

Mahendra Pal Singh

Tandrika Chattopadhyay

Original Assignee

Nat Institute Of Immunology

Indian Inst Scient

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-04-07

Filing date

2009-03-20

Publication date

2014-03-31

2009-03-20 Application filed by Nat Institute Of Immunology, Indian Inst Scient filed Critical Nat Institute Of Immunology

2014-03-31 Publication of PL2133091T3 publication Critical patent/PL2133091T3/pl

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 2
102000004877 Insulin Human genes 0.000 title 1
108090001061 Insulin Proteins 0.000 title 1
230000000712 assembly Effects 0.000 title 1
238000000429 assembly Methods 0.000 title 1
206010012601 diabetes mellitus Diseases 0.000 title 1
229940125396 insulin Drugs 0.000 title 1
239000000203 mixture Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Communicable Diseases (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Oncology (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

PL09155775T 2008-04-07 2009-03-20 Kompozycje zawierające supramolekularne układy insuliny użyteczne do leczenia cukrzycy PL2133091T3 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IN914DE2008		2008-04-07
EP09155775.1A EP2133091B1 (en)	2008-04-07	2009-03-20	Compositions comprising supramolecular insulin assemblies useful for the treatment of diabetes

Publications (1)

Publication Number	Publication Date
PL2133091T3 true PL2133091T3 (pl)	2014-03-31

Family

ID=40841040

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL09155775T PL2133091T3 (pl)	2008-04-07	2009-03-20	Kompozycje zawierające supramolekularne układy insuliny użyteczne do leczenia cukrzycy

Country Status (12)

Country	Link
US (3)	US20110034385A1 (pl)
EP (2)	EP2282763B1 (pl)
JP (3)	JP2011516541A (pl)
CN (1)	CN102088997A (pl)
AU (2)	AU2008354530B2 (pl)
CA (1)	CA2720864C (pl)
ES (1)	ES2425491T3 (pl)
HR (1)	HRP20130772T1 (pl)
PL (1)	PL2133091T3 (pl)
PT (1)	PT2133091E (pl)
WO (1)	WO2009125423A2 (pl)
ZA (2)	ZA200902374B (pl)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2395096T3 (es)	1999-06-29	2013-02-08	Mannkind Corporation	Purificación y estabilización de agentes farmacéuticos a base de péptidos y proteínas
US9006175B2 (en)	1999-06-29	2015-04-14	Mannkind Corporation	Potentiation of glucose elimination
JP4681231B2 (ja)	2002-03-20	2011-05-11	マンカインドコーポレイション	吸入装置
ATE486064T1 (de)	2004-08-20	2010-11-15	Mannkind Corp	Katalyse der diketopiperazinsynthese
HUE025151T2 (en)	2004-08-23	2016-01-28	Mannkind Corp	Diceto-piperazine salts for drug delivery
MX373000B (es)	2005-09-14	2020-05-21	Mannkind Corp	Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
CN104383546B (zh)	2006-02-22	2021-03-02	曼金德公司	用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法
DE102006033167A1 (de) *	2006-07-10	2008-01-24	Gelita Ag	Verwendung von Gelatine und einem Vernetzungsmittel zur Herstellung eines vernetzenden medizinischen Klebers
KR20100090692A (ko) *	2007-10-24	2010-08-16	맨카인드 코포레이션	활성제의 전달
US8785396B2 (en)	2007-10-24	2014-07-22	Mannkind Corporation	Method and composition for treating migraines
MY155524A (en)	2008-06-13	2015-10-30	Mannkind Corp	A dry powder inhaler and system for drug delivery
US8485180B2 (en)	2008-06-13	2013-07-16	Mannkind Corporation	Dry powder drug delivery system
EP2609954B1 (en)	2008-06-20	2021-12-29	MannKind Corporation	An interactive apparatus for real-time profiling of inhalation efforts
TWI494123B (zh)	2008-08-11	2015-08-01	Mannkind Corp	超快起作用胰島素之用途
US8314106B2 (en)	2008-12-29	2012-11-20	Mannkind Corporation	Substituted diketopiperazine analogs for use as drug delivery agents
US8538707B2 (en)	2009-03-11	2013-09-17	Mannkind Corporation	Apparatus, system and method for measuring resistance of an inhaler
AU2010259943C1 (en)	2009-06-12	2016-03-03	Mannkind Corporation	Diketopiperazine microparticles with defined specific surface areas
JP5784622B2 (ja)	2009-11-03	2015-09-24	マンカインドコーポレ−ション	吸入活動をシミュレートするための装置及び方法
RU2531455C2 (ru)	2010-06-21	2014-10-20	Маннкайнд Корпорейшн	Системы и способы доставки сухих порошковых лекарств
MX353285B (es)	2011-04-01	2018-01-05	Mannkind Corp	Paquete de blister para cartuchos farmaceuticos.
US20140170108A1 (en) *	2011-05-19	2014-06-19	National Institute Of Immunology	Compositions useful for the treatment of inflammatory disease or disorders
WO2012174472A1 (en)	2011-06-17	2012-12-20	Mannkind Corporation	High capacity diketopiperazine microparticles
HK1201475A1 (en)	2011-10-24	2015-09-04	Mannkind Corporation	Methods and compositions for treating pain
WO2013102921A2 (en) *	2011-11-17	2013-07-11	Sanzyme Limited	Hcg - newer treatment modality for type 2 diabetes mellitus (t2dm)
AU2013289957B2 (en)	2012-07-12	2017-02-23	Mannkind Corporation	Dry powder drug delivery systems and methods
WO2014054046A1 (en) *	2012-10-04	2014-04-10	Gavish-Galilee Bio Applications Ltd	Ordered reversible fibrils, aggregates and multimers of proteins and uses thereof
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
WO2014066856A1 (en)	2012-10-26	2014-05-01	Mannkind Corporation	Inhalable influenza vaccine compositions and methods
EP2925345B1 (en)	2012-12-03	2018-09-05	Merck Sharp & Dohme Corp.	Method for making o-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues
HUE035803T2 (en)	2012-12-21	2018-05-28	Sanofi Sa	Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
BR112015023168B1 (pt)	2013-03-15	2021-08-10	Mannkind Corporation	Composição de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina cristalina, método de produção de partículas de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina e uso de uma composição de dicetopiperazina cristalina
BR122019026637B1 (pt)	2013-07-18	2023-09-26	Mannkind Corporation	Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco
CA2920488C (en)	2013-08-05	2022-04-26	Mannkind Corporation	Insufflation apparatus and methods
WO2015086728A1 (en)	2013-12-13	2015-06-18	Sanofi	Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201609797A (zh)	2013-12-13	2016-03-16	賽諾菲公司	雙重ｇｌｐ－１／升糖素受體促效劑
EP3080154B1 (en)	2013-12-13	2018-02-07	Sanofi	Dual glp-1/gip receptor agonists
WO2015086730A1 (en)	2013-12-13	2015-06-18	Sanofi	Non-acylated exendin-4 peptide analogues
US10307464B2 (en)	2014-03-28	2019-06-04	Mannkind Corporation	Use of ultrarapid acting insulin
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
US10561806B2 (en)	2014-10-02	2020-02-18	Mannkind Corporation	Mouthpiece cover for an inhaler
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh)	2015-07-10	2017-02-16	賽諾菲公司	作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
CN106977609B (zh) *	2017-04-19	2020-07-28	刘崇东	一种融合蛋白、制备方法及其应用
CN111714643A (zh) *	2019-03-22	2020-09-29	约翰霍普金斯大学	一种单宁酸/Fe3+纳米颗粒体系、药物递送方法
US10799564B1 (en)	2019-05-06	2020-10-13	Baxter International Inc.	Insulin premix formulation and product, methods of preparing same, and methods of using same

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5714167A (en) *	1992-06-15	1998-02-03	Emisphere Technologies, Inc.	Active agent transport systems
GB9108634D0 (en) *	1991-04-23	1991-06-12	Ciba Geigy	Pharmaceutical compositions
CO4970787A1 (es) *	1997-12-23	2000-11-07	Lilly Co Eli	Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
FR2786098B1 (fr) *	1998-11-20	2003-05-30	Flamel Tech Sa	Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s), suspension colloidale les comprenant et leurs procedes de fabrication
US6506724B1 (en)	1999-06-01	2003-01-14	Amylin Pharmaceuticals, Inc.	Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
US20020099013A1 (en) *	2000-11-14	2002-07-25	Thomas Piccariello	Active agent delivery systems and methods for protecting and administering active agents
WO2002067969A2 (en) *	2001-02-21	2002-09-06	Medtronic Minimed, Inc.	Stabilized insulin formulations
FR2822834B1 (fr) *	2001-04-02	2005-02-25	Flamel Tech Sa	Suspension colloidale de nanoparticules a base de copolymeres amphiphile pour la vectorisation de principes actifs et leur mode de preparation
US7655618B2 (en) *	2002-12-27	2010-02-02	Diobex, Inc.	Compositions and methods for the prevention and control of insulin-induced hypoglycemia
KR101308912B1 (ko) *	2003-06-03	2013-09-23	노보 노르디스크 에이/에스	안정화된 약학적 펩티드 조성물
CN101415724B (zh) *	2003-06-30	2015-12-02	特拉维夫大学未来科技开发有限公司	肽、抗肽抗体以及用它们来诊断和治疗淀粉样蛋白相关疾病的方法
EP1824460B1 (en) *	2004-11-10	2014-12-24	Tolmar Therapeutics, Inc.	A stabilized polymeric delivery system
US20060281669A1 (en) *	2005-06-13	2006-12-14	Yue Samuel K	Method and compositions for the treatment of diabetes and related complications
WO2007047834A2 (en) *	2005-10-18	2007-04-26	Biocon Limited	Oral peptide conjugates for metabolic diseases
US20090148401A1 (en) *	2005-12-05	2009-06-11	Trinity Biosystems, Inc.	Methods and compositions for needleless delivery of binding partners
US8440214B2 (en) *	2006-01-31	2013-05-14	Boston Scientific Scimed, Inc.	Medical devices for therapeutic agent delivery with polymeric regions that contain copolymers having both soft segments and uniform length hard segments
EP2120859B1 (en) *	2006-12-21	2013-11-20	Stryker Corporation	Sustained-release formulations comprising bmp-7 crystals

2008
- 2008-10-13 EP EP08873840.6A patent/EP2282763B1/en not_active Not-in-force
- 2008-10-13 AU AU2008354530A patent/AU2008354530B2/en not_active Ceased
- 2008-10-13 CN CN2008801296299A patent/CN102088997A/zh active Pending
- 2008-10-13 US US12/936,709 patent/US20110034385A1/en not_active Abandoned
- 2008-10-13 CA CA2720864A patent/CA2720864C/en not_active Expired - Fee Related
- 2008-10-13 WO PCT/IN2008/000664 patent/WO2009125423A2/en not_active Ceased
- 2008-10-13 JP JP2011503551A patent/JP2011516541A/ja active Pending
2009
- 2009-03-06 AU AU2009200906A patent/AU2009200906B2/en not_active Ceased
- 2009-03-20 PL PL09155775T patent/PL2133091T3/pl unknown
- 2009-03-20 EP EP09155775.1A patent/EP2133091B1/en not_active Not-in-force
- 2009-03-20 ES ES09155775T patent/ES2425491T3/es active Active
- 2009-03-20 PT PT91557751T patent/PT2133091E/pt unknown
- 2009-04-02 JP JP2009090219A patent/JP5592077B2/ja not_active Expired - Fee Related
- 2009-04-06 ZA ZA200902374A patent/ZA200902374B/xx unknown
- 2009-04-07 US US12/419,669 patent/US8426362B2/en not_active Expired - Fee Related
2010
- 2010-10-06 ZA ZA2010/07114A patent/ZA201007114B/en unknown
2013
- 2013-03-18 US US13/845,209 patent/US8940691B2/en not_active Expired - Fee Related
- 2013-08-16 HR HRP20130772AT patent/HRP20130772T1/hr unknown
2014
- 2014-08-28 JP JP2014173649A patent/JP5964373B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
HRP20130772T1 (hr)	2013-12-06
CA2720864C (en)	2017-07-04
EP2133091B1 (en)	2013-05-22
CA2720864A1 (en)	2009-10-15
US8426362B2 (en)	2013-04-23
EP2133091A3 (en)	2010-07-14
PT2133091E (pt)	2013-08-28
EP2133091A2 (en)	2009-12-16
ES2425491T3 (es)	2013-10-15
US20090258818A1 (en)	2009-10-15
JP2011516541A (ja)	2011-05-26
US8940691B2 (en)	2015-01-27
US20130217621A1 (en)	2013-08-22
JP2009249382A (ja)	2009-10-29
AU2008354530A1 (en)	2009-10-15
AU2009200906B2 (en)	2014-04-03
ZA200902374B (en)	2009-12-30
ZA201007114B (en)	2011-06-29
WO2009125423A2 (en)	2009-10-15
EP2282763A2 (en)	2011-02-16
JP5592077B2 (ja)	2014-09-17
AU2008354530B2 (en)	2014-02-27
WO2009125423A3 (en)	2010-03-04
EP2282763B1 (en)	2013-12-11
AU2009200906A1 (en)	2010-03-25
CN102088997A (zh)	2011-06-08
US20110034385A1 (en)	2011-02-10
JP5964373B2 (ja)	2016-08-03
JP2014231520A (ja)	2014-12-11

Publication	Publication Date	Title
ZA200902374B (en)	2009-12-30	Compositions useful for the treatment of diabetes
ZA201006367B (en)	2011-05-25	Oxadiazoanthracene compounds for the treatment of diabetes
IL225198A (en)	2016-02-29	Aminotetrahydropyrenic Compounds, Pharmaceutical Preparations Containing Them and Their Use in the Treatment of Diabetes
GB0802403D0 (en)	2008-03-12	Compositions for the treatment of oxidative stress
ZA201006827B (en)	2011-05-25	Carboxamide-heteroaryl derivatives for the treatment of diabetes
PL2247602T3 (pl)	2013-08-30	Pochodne O-glukuronido-adamantylowe jako inhibitory dipeptydylopeptydazy IV do leczenia cukrzycy
ZA200905970B (en)	2012-08-29	Pharmaceutical composition for treatment of diabetic complications
IL211313A0 (en)	2011-04-28	Compounds, compositions and methods for the treatment of ??-amyloid diseases and synucleinopathies
PT2315587T (pt)	2018-01-31	Produto que contém macitentan, composição farmacêutica que o contém e uso de macitentan
IL199829A0 (en)	2010-04-15	Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome
IL206904A0 (en)	2010-12-30	Beta--amino acid derivatives for treatment of diabetes
IL209723A0 (en)	2011-02-28	Tetrahydrocinnolines as 11 beta hsd1 inhibitors for diabetes
EP2320879A4 (en)	2014-03-05	PHARMACEUTICAL COMPOSITION COMPRISES JASMONATES
GB0812019D0 (en)	2008-08-06	Insulin
IL211267A0 (en)	2011-04-28	Oxadiazole derivatives for the treatment of diabetes
AU2009215883A8 (en)	2010-09-09	Blood substitute solution
PL2323625T3 (pl)	2017-01-31	Nowa kompozycja do leczenia pigmentacji wybroczynowych
IL209947A (en)	2014-07-31	Compounds for the treatment of corneal inflammation
IL207668A0 (en)	2010-12-30	Beloxepin, its enantiomers, and analogs thereof for the treatment of pain
PL2252302T3 (pl)	2014-05-30	Kompozycja do leczenia zapalenia kości i stawów
IL200192A0 (en)	2010-04-15	Composition useful for the treatment of type 2 diabetes
EP2402342A4 (en)	2012-09-19	PHARMACEUTICAL COMPOSITION FOR TREATING TYPE 2 DIABETES
ZA201100529B (en)	2012-03-28	Solid pharmaceutical composition comprising exemestane
EP2352541A4 (en)	2014-01-08	CATHETER LOCK COMPOSITION
PL384259A1 (pl)	2009-07-20	Kompozycja farmaceutyczna do leczenia chorób skórnych